[HTML][HTML] Retinitis pigmentosa: novel therapeutic targets and drug development

KY Wu, M Kulbay, D Toameh, AQ Xu, A Kalevar… - Pharmaceutics, 2023 - mdpi.com
Retinitis pigmentosa (RP) is a heterogeneous group of hereditary diseases characterized by
progressive degeneration of retinal photoreceptors leading to progressive visual decline. It …

Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention

S Strong, G Liew, M Michaelides - British journal of ophthalmology, 2017 - bjo.bmj.com
Hereditary retinal diseases are now the leading cause of blindness certification in the
working age population (age 16–64 years) in England and Wales, of which retinitis …

Retinitis pigmentosa: current clinical management and emerging therapies

XTA Nguyen, L Moekotte, AS Plomp… - International journal of …, 2023 - mdpi.com
Retinitis pigmentosa (RP) comprises a group of inherited retinal dystrophies characterized
by the degeneration of rod photoreceptors, followed by the degeneration of cone …

Intravitreal injection of therapeutic agents

GA Peyman, EM Lad, DM Moshfeghi - Retina, 2009 - journals.lww.com
Background: Intravitreal injection (IVI) with administration of various pharmacological agents
is a mainstay of treatment in ophthalmology for endopthalmitis, viral retinitis, age-related …

Intravitreal steroids for the treatment of retinal diseases

V Sarao, D Veritti, F Boscia… - The Scientific World …, 2014 - Wiley Online Library
Diabetic macular edema (DME), pseudophakic cystoid macular edema (CME), age‐related
macular degeneration (AMD), retinal vascular occlusion (RVO), and uveitis are ocular …

The prevalence of cystoid macular oedema in retinitis pigmentosa patients determined by optical coherence tomography

M Hajali, GA Fishman, RJ Anderson - British Journal of Ophthalmology, 2008 - bjo.bmj.com
Aims: To determine the prevalence of cystoid macular oedema (CMO) in retinitis pigmentosa
(RP) patients of various genetic subtypes using optical coherence tomography (OCT) …

Intravitreal triamcinolone acetonide: a change in a paradigm

JB Jonas - Ophthalmic research, 2006 - karger.com
Background: Based on experimental studies and clinical observations by Robert Machemer,
Gholam Peyman and others, the vitreous cavity has increasingly been used as a reservoir of …

Retinitis pigmentosa: review of current treatment

AL Wang, DK Knight, TV Thanh-thao… - International …, 2019 - journals.lww.com
Retinitis pigmentosa (RP) is a diverse group of hereditary degenerations characterized by
progressive dysfunction of predominantly rod followed by cone photoreceptors. Typical RP …

Treatment of cystoid macular edema secondary to retinitis pigmentosa: a systematic review

M Bakthavatchalam, FHP Lai, SS Rong, DS Ng… - Survey of …, 2018 - Elsevier
There are various treatments for cystoid macular edema (CME) secondary to retinitis
pigmentosa; however, the evidence for these treatments has not been previously …

Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases

JB Jonas - Acta Ophthalmologica Scandinavica, 2005 - Wiley Online Library
Intravitreal triamcinolone acetonide (IVTA) has increasingly been applied as treatment for
various intraocular neovascular and oedematous diseases. Comparing the various diseases …